3SBio Inc (1530 HK): Hair Product Acts as the Savior; Marginal Growth of Flagship Drug

513 Views01 Dec 2022 13:38

SUMMARY

Mandi, OTC alopecia drug of 3SBio Inc (1530 HK), reported revenue growth of 42% y/y in 1H22 and gained 70bps market share over the last six months.
With the resurgence of COVID-19 in China interrupting the regular operations of outpatient services at medical institutions, 3SBio’s performance is expected to be affected in near-term.
3SBio is preparing to launch its new drug nalfuraphine hydrochloride orally disintegrating tablets for liver and kidney disease pruritus in China.

Related Insights

Trending Collections

Trending Insights

Top Unpaywalled Insights

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream